<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35986269</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7525</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Health and quality of life outcomes</Title><ISOAbbreviation>Health Qual Life Outcomes</ISOAbbreviation></Journal><ArticleTitle>Impact of long-COVID on health-related quality of life in Japanese COVID-19 patients.</ArticleTitle><Pagination><StartPage>125</StartPage><MedlinePgn>125</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">125</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12955-022-02033-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The empirical basis for a quantitative assessment of the disease burden imposed by long-COVID is currently scant. We aimed to inform the disease burden caused by long-COVID in Japan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a cross sectional self-report questionnaire survey. The questionnaire was mailed to 526 eligible patients, who were recovered from acute COVID-19 in April 2021. Answers were classified into two groups; participants who have no symptom and those who have any ongoing prolonged symptoms that lasted longer than four weeks at the time of the survey. We estimated the average treatment effect (ATE) of ongoing prolonged symptoms on EQ-VAS and EQ-5D-3L questionnaire using inverse probability weighting. In addition to symptom prolongation, we investigated whether other factors (including demography, lifestyle, and acute severity) were associated with low EQ-VAS and EQ-5D-3L values, by multivariable linear regression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">349 participants reported no symptoms and 108 reported any symptoms at the time of the survey. The participants who reported any symptoms showed a lower average value on the EQ-VAS (69.9 vs 82.8, respectively) and on the EQ-5D-3L (0.85 vs 0.96, respectively) than those reporting no symptoms considering the ATE of ongoing prolonged symptoms. The ATE of ongoing prolonged symptoms on EQ-VAS was -&#xa0;12.9 [95% CI -&#xa0;15.9 to -&#xa0;9.8], and on the EQ-5D-3L it was -&#xa0;0.11 [95% CI -&#xa0;0.13 to -&#xa0;0.09], implying prolonged symptoms have a negative impact on patients' EQ-VAS and EQ-5D-3L score. In multivariable linear regression, only having prolonged symptoms was associated with lower scores (-&#xa0;11.7 [95% CI -&#xa0;15.0 to -&#xa0;8.5] for EQ-VAS and -&#xa0;0.10 [95% CI -&#xa0;0.13 to -&#xa0;0.08] for EQ-5D-3L).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Due to their long duration, long-COVID symptoms represent a substantial disease burden expressed in impact on health-related quality of life.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsuzuki</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5732-846X</Identifier><AffiliationInfo><Affiliation>AMR Clinical Reference Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. stsuzuki@hosp.ncgm.go.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Health Economics Research &amp; Modelling Infectious Diseases, Vaccine &amp; Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Prinsstraat 13, 2000, Antwerp, Belgium. stsuzuki@hosp.ncgm.go.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. stsuzuki@hosp.ncgm.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazato</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terada</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morioka</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emerging and Re-Emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmagari</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AMR Clinical Reference Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emerging and Re-Emerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beutels</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Health Economics Research &amp; Modelling Infectious Diseases, Vaccine &amp; Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Prinsstraat 13, 2000, Antwerp, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>18K17369</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>20K10546</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>20A05</GrantID><Agency>National Center for Global Health and Medicine</Agency><Country/></Grant><Grant><GrantID>JP20fk0108502</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>Research for risk assessment</GrantID><Agency>Ministry of Health, Labour and Welfare</Agency><Country/></Grant><Grant><GrantID>implementation of crisis management functions for emerging</GrantID><Agency>Ministry of Health, Labour and Welfare</Agency><Country/></Grant><Grant><GrantID>re-emerging infectious diseases</GrantID><Agency>Ministry of Health, Labour and Welfare</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Qual Life Outcomes</MedlineTA><NlmUniqueID>101153626</NlmUniqueID><ISSNLinking>1477-7525</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Disease burden</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword></KeywordList><CoiStatement>PB reports grants from Pfizer, GlaxoSmithKline, and the European Commission IMI, unrelated to this&#xa0;work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35986269</ArticleId><ArticleId IdType="pmc">PMC9388960</ArticleId><ArticleId IdType="doi">10.1186/s12955-022-02033-6</ArticleId><ArticleId IdType="pii">10.1186/s12955-022-02033-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozaki I, Miyano S. The necessity of continuous international cooperation for establishing the coronavirus disease 2019 diagnostic capacity despite the challenges of fighting the outbreak in home countries. GHM. 2020;2:145&#x2013;147. doi: 10.35772/ghm.2020.01023.</Citation><ArticleIdList><ArticleId IdType="doi">10.35772/ghm.2020.01023</ArticleId><ArticleId IdType="pmc">PMC7731053</ArticleId><ArticleId IdType="pubmed">33330797</ArticleId></ArticleIdList></Reference><Reference><Citation>del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA. 2020;324:1723&#x2013;1724. doi: 10.1001/jama.2020.19719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>UK guidelines for managing long-term effects of COVID-19. Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00847-3/fulltext</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102038</ArticleId><ArticleId IdType="pubmed">33965081</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Taylor S. NICE guideline on long Covid. BMJ. 2020;371:m4938. doi: 10.1136/bmj.m4938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4938</ArticleId><ArticleId IdType="pubmed">33361141</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long Covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020;7:ofaa507. doi: 10.1093/ofid/ofaa507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa507</ArticleId><ArticleId IdType="pmc">PMC7665672</ArticleId><ArticleId IdType="pubmed">33230486</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. &#x2018;Long-COVID&#x2019;: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396&#x2013;398. doi: 10.1136/thoraxjnl-2020-215818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz YMJ, Herck MV, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542&#x2013;2020. doi: 10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:993. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594&#x2013;600. doi: 10.1016/j.bbi.2020.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.07.037</ArticleId><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021;93:1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D, Menegaldo A, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg. 2020;146:729. doi: 10.1001/jamaoto.2020.1379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2020.1379</ArticleId><ArticleId IdType="pmc">PMC7333173</ArticleId><ArticleId IdType="pubmed">32614442</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5:1265. doi: 10.1001/jamacardio.2020.3557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)&#x2014;a systematic review and meta-analysis. J Med Virol US. 2022;94:253&#x2013;262. doi: 10.1002/jmv.27309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Riveros C, Clepier B, Desvarieux M, Collet C, Yordanov Y, et al. Development and validation of the long Covid symptom and impact tools, a set of patient-reported instruments constructed from patients&#x2019; lived experience. Clin Infect Dis. 2021;74:278&#x2013;287. doi: 10.1093/cid/ciab352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, McCarthy D, et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life and participation. Am J Phys Med Rehabil. 2022;101:48. doi: 10.1097/PHM.0000000000001910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001910</ArticleId><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink TT, Marques HHS, Gualano B, Lindoso L, Bain V, Astley C, et al. Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: a prospective study in a Latin American tertiary hospital. Clinics (Sao Paulo) 2021;76:e3511. doi: 10.6061/clinics/2021/e3511.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2021/e3511</ArticleId><ArticleId IdType="pmc">PMC8595593</ArticleId><ArticleId IdType="pubmed">34852145</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. Clin Infect Dis. 2020;73:e3677&#x2013;e3689. doi: 10.1093/cid/ciaa1470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1470</ArticleId><ArticleId IdType="pmc">PMC7543311</ArticleId><ArticleId IdType="pubmed">32986793</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale: L. Erlbaum Associates; 1988.</Citation></Reference><Reference><Citation>R Core Team . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2018.</Citation></Reference><Reference><Citation>Rabin R, Gudex C, Selai C, Herdman M. From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire. Value Health. 2014;17:70&#x2013;76. doi: 10.1016/j.jval.2013.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2013.10.006</ArticleId><ArticleId IdType="pubmed">24438719</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341&#x2013;353. doi: 10.1002/hec.673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.673</ArticleId><ArticleId IdType="pubmed">12007165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41&#x2013;55. doi: 10.1093/biomet/70.1.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095&#x2013;1108. doi: 10.1097/00005650-199711000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199711000-00002</ArticleId><ArticleId IdType="pubmed">9366889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Kim HJ, Lonjon G, Zhu Y, Group written on behalf of AB-DCTC Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16&#x2013;16. doi: 10.21037/atm.2018.12.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2018.12.10</ArticleId><ArticleId IdType="pmc">PMC6351359</ArticleId><ArticleId IdType="pubmed">30788363</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston R, Jones K, Manley D. Confounding and collinearity in regression analysis: a cautionary tale and an alternative procedure, illustrated by studies of British voting behaviour. Qual Quant. 2018;52:1957&#x2013;1976. doi: 10.1007/s11135-017-0584-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11135-017-0584-6</ArticleId><ArticleId IdType="pmc">PMC5993839</ArticleId><ArticleId IdType="pubmed">29937587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcclure NS, Sayah FA, Xie F, Luo N, Johnson JA. Instrument-defined estimates of the minimally important difference for EQ-5D-5L Index Scores. Value Health. 2017;20:644&#x2013;650. doi: 10.1016/j.jval.2016.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2016.11.015</ArticleId><ArticleId IdType="pubmed">28408007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor-Barriuso R, P&#xe9;rez-G&#xf3;mez B, Hern&#xe1;n MA, P&#xe9;rez-Olmeda M, Yotti R, Oteo-Iglesias J, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. BMJ. 2020;371:m4509. doi: 10.1136/bmj.m4509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4509</ArticleId><ArticleId IdType="pmc">PMC7690290</ArticleId><ArticleId IdType="pubmed">33246972</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Marziano V, et al. Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020. Eurosurveillance. 2020;25:2001383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7459272</ArticleId><ArticleId IdType="pubmed">32762797</ArticleId></ArticleIdList></Reference><Reference><Citation>van Asten L, Harmsen CN, Stoeldraijer L, Klinkenberg D, Teirlinck AC, de Lange MMA, et al. Excess deaths during influenza and coronavirus disease and infection-fatality rate for severe acute respiratory syndrome coronavirus 2, the Netherlands. Emerg Infect Dis. 2021;27:411&#x2013;420. doi: 10.3201/eid2702.202999.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2702.202999</ArticleId><ArticleId IdType="pmc">PMC7853586</ArticleId><ArticleId IdType="pubmed">33395381</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuzuki S, Yoshihara K. The characteristics of influenza-like illness management in Japan. BMC Public Health. 2020;20:568. doi: 10.1186/s12889-020-08603-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-08603-x</ArticleId><ArticleId IdType="pmc">PMC7189553</ArticleId><ArticleId IdType="pubmed">32345248</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson G, Carson G, Sigfrid L, Olliaro P, Norton A, Paparella G, et al. Research priorities for long Covid: refined through an international multi-stakeholder forum. BMC Med. 2021;19:84. doi: 10.1186/s12916-021-01947-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-01947-0</ArticleId><ArticleId IdType="pmc">PMC8009733</ArticleId><ArticleId IdType="pubmed">33785027</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) PNAS Natl Acad Sci. 2020;117:17720&#x2013;17726. doi: 10.1073/pnas.2008410117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2008410117</ArticleId><ArticleId IdType="pmc">PMC7395502</ArticleId><ArticleId IdType="pubmed">32647056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilishvili T. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel&#x2014;33 U.S sites, January&#x2013;March 2021. MMWR Morb Mortal Wkly Rep. 2021;70:753. doi: 10.15585/mmwr.mm7020e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7020e2</ArticleId><ArticleId IdType="pmc">PMC8136422</ArticleId><ArticleId IdType="pubmed">34014909</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance &#x2014; One Hospital, California, July 15&#x2013;September 23, 2021, and Dec. MMWR Morb Mortal Wkly Rep. 2022;71:217&#x2013;223. doi: 10.15585/mmwr.mm7106e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7106e2</ArticleId><ArticleId IdType="pmc">PMC8830624</ArticleId><ArticleId IdType="pubmed">35143466</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouzid D, Visseaux B, Kassasseya C, Daoud A, F&#xe9;my F, Hermand C, et al. Comparison of patients infected with delta versus omicron COVID-19 variants presenting to Paris Emergency Departments. Ann Intern Med. 2022. 10.7326/m22-0308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8941485</ArticleId><ArticleId IdType="pubmed">35286147</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>